Patients with type 2 diabetes, cardiovascular illness and kidney disease were randomized to receive jardiance or placebo. Baseline renal parameters were eGFR 30-60 and albuminuria of >300 mg/day.
Study found that jardiance improved outcomes significantly: all-cause mortality by 24%, cardiovascular death by 29%, all-cause hospitalization by 19%, and heart failure hospitalization by 39%.
Findings are overall consistent with prior clinical trial results.
Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus and established cardiovascular disease in the EMPA-REG OUTCOME trial. Urinary glucose excretion with empagliflozin decreases with declining renal function, resulting in less potency for glucose lowering in patients with kidney disease. We investigated the effects of empagliflozin on clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease.
Patients with type 2 diabetes mellitus, established cardiovascular disease, and estimated glomerular filtration rate, eGFR ≥30 at screening were randomized to receive empagliflozin 10 mg, empagliflozin 25 mg, or placebo once daily in addition to standard of care.
We analyzed cardiovascular death, hospitalization for heart failure, all-cause hospitalization, and all-cause mortality in patients with prevalent kidney disease, defined as eGFR <60 and/or urine albumin-creatinine ratio >300 mg/g at baseline. Additional analyses were performed in subgroups by baseline eGFR (<45, 45–<60, 60–<90, ≥90) and baseline urine albumin-creatinine ratio (>300, 30–≤300, <30 mg/g).
Of 7,020 patients treated, 2,250 patients had prevalent kidney disease at baseline, of whom 67% had a diagnosis of type 2 diabetes mellitus for >10 years, 58% were receiving insulin, and 84% were taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
In patients with prevalent kidney disease at baseline, empagliflozin reduced the risk of cardiovascular death by 29% (p<0.05) compared with placebo, the risk of all-cause mortality by 24% (p<0.05), the risk of hospitalization for heart failure by 39% (p<0.05), and the risk of all-cause hospitalization by 19% (p<0.05).
Effects of empagliflozin on these outcomes were consistent across categories of eGFR and urine albumin-creatinine ratio at baseline and across the 2 doses studied. The adverse event profile of empagliflozin in patients with eGFR <60 was consistent with the overall trial population.
Empagliflozin improved clinical outcomes and reduced mortality in vulnerable patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease.